Business
Isodiol International Inc. Upgrades to OTCQB
Isodiol International Inc. Upgrades to OTCQB.
About this update from Isodiol International Inc
[{"type":"text","content":"\n\n VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products, announced today that Isodiol’s common shares have been approved for trading on the OTCQB Venture Market in the United States. The trading symbol will remain as ISOLF.\n The OTCQB is the ideal exchange for emerging companies.  To be eligible for the OTCQB, companies must be up to date in reporting with the U.S. Securities Exchange Commission, meet a minimum price bid test, and undergo an annual verification and management certification process.  These standards and regulations will provide investors with confidence and enhance their trading experiences.    “We are very pleased with this OTCQB listing.  Listing on the OTCQB is part of Isodiol’s overall strategy to increase awareness to international investors,” said Marcos Agramont, CEO of Isodiol.  “This listing will provide the Company with a significant trading platform for international shareholders and future investors, while making the Company itself easily available to American investors.” For more information on Isodiol, please visit www.isodiol.com  About Isodiol International Inc. Isodiol International Inc. is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe. Join Us On Facebook: https://www.facebook.com/isodiol/Twitter: @isodiol ON BEHALF OF THE BOARDMarcos Agramont, CEO & Director INVESTOR RELATIONS:[email protected] MEDIA CONTACT:Carrie Booze North 6th Agency 212...